Kura Oncology (NASDAQ:KURA) Rating Lowered to “Hold” at StockNews.com

Kura Oncology (NASDAQ:KURA) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

Several other equities analysts have also issued reports on the company. JMP Securities reaffirmed a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. UBS Group decreased their target price on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Finally, Bank of America decreased their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Stock Performance

NASDAQ:KURA opened at $7.27 on Tuesday. The firm has a market capitalization of $587.09 million, a PE ratio of -3.08 and a beta of 0.85. The business’s fifty day moving average price is $7.81 and its 200 day moving average price is $12.61. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 12 month low of $6.79 and a 12 month high of $23.48.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million. On average, sell-side analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 11,729 shares of company stock worth $92,307. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. grew its stake in Kura Oncology by 11.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock worth $144,000 after acquiring an additional 1,750 shares during the period. Rhumbline Advisers grew its stake in Kura Oncology by 2.0% in the 4th quarter. Rhumbline Advisers now owns 99,991 shares of the company’s stock worth $871,000 after acquiring an additional 1,923 shares during the period. Harbor Capital Advisors Inc. grew its stake in Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after acquiring an additional 2,076 shares during the period. Teacher Retirement System of Texas grew its stake in Kura Oncology by 19.9% in the 4th quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock worth $120,000 after acquiring an additional 2,285 shares during the period. Finally, MetLife Investment Management LLC grew its stake in Kura Oncology by 6.6% in the 4th quarter. MetLife Investment Management LLC now owns 44,828 shares of the company’s stock worth $390,000 after acquiring an additional 2,776 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.